## Clinical Context This patient has early-stage gastric cancer (T2 N0 M0) — a potentially curable situation. The key decision is whether to pursue endoscopic or surgical resection based on depth of invasion and lymph node status. ## Staging and Resectability **Key Point:** T2 N0 M0 gastric cancer is surgically resectable with curative intent. The depth of invasion (T2 = muscularis propria involvement) and absence of lymph node metastases make this patient an ideal candidate for gastrectomy with D2 lymphadenectomy. **High-Yield:** Endoscopic resection (EMR/ESD) is reserved for early gastric cancer (EGC) with very low risk of lymph node metastasis: - T1a (mucosal, <500 μm depth) without ulceration - T1b (mucosal, 500–1000 μm) with strict criteria - Intestinal histology, well/moderately differentiated - <3 cm diameter This patient's T2 disease exceeds the endoscopic criteria and carries ~15–20% risk of lymph node involvement even with N0 on imaging. ## Surgical Strategy **Clinical Pearl:** For T2 N0 gastric cancer: - **Location matters:** Distal (antral) lesions → subtotal gastrectomy; proximal (cardia/fundus) → total gastrectomy - **Lymphadenectomy:** D2 dissection (removal of perigastric + regional nodes) is standard for curative intent - **Margins:** 5 cm proximal and distal margins for safety - **Adjuvant therapy:** Not routinely required for T2 N0, but may be considered if high-risk features (poor differentiation, perineural invasion) are present on final pathology | Feature | Endoscopic Resection | Surgical Resection | |---------|----------------------|--------------------| | **Depth** | T1a/selected T1b | T2, T3, T4 | | **Node risk** | <5% | 15–20% (T2 N0) | | **Margins** | Limited | 5 cm proximal/distal | | **Lymphadenectomy** | None | D2 standard | | **Morbidity** | Low | Moderate | | **Recurrence (T2)** | High if endoscopic | Low if surgical | **Mnemonic:** **ENDO-T1, SURGERY-T2+** — Endoscopic resection for T1 EGC; Surgical resection for T2 and deeper gastric cancers. ## Why Not the Other Options? EMR is not appropriate for T2 disease because it cannot achieve adequate lymphadenectomy and carries unacceptably high recurrence risk. Neoadjuvant chemotherapy is not indicated for T2 N0 disease; it is reserved for locally advanced (T3/T4 or N+) tumors. Observation is never appropriate for confirmed gastric cancer — it allows disease progression and metastasis. [cite:Robbins 10e Ch 17]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.